InVivo Therapeutics

The mission of InVivo Therapeutics is to provide society with superior neurological products and services by delivering novel approaches to the treatment of disease that will improve the quality of life and satisfy the needs of those who live with spinal cord injury. We also seek to empower our employees to create new treatment options for spinal cord injuries with the expectation that they will have the opportunity to make a difference in the lives of all people impacted by these injuries. Our business is preserving and improving human life. We value, above all, our ability to serve everyone who can benefit from the appropriate use of our products and services, thereby providing lasting consumer satisfaction. We recognize that our ability to excel and to most competitively meet society’s and customers’ needs depends on the integrity, knowledge, imagination/creativity, skill, diversity, practicality and teamwork of our employees, and we value these qualities above all else. To this end, we strive to create an environment of mutual respect, encouragement and teamwork—an environment that rewards commitment and performance and is responsive to the needs of our employees and their families. Dr. Langer was awarded the 2006 National Medal of Science by President George W. Bush. InVivo Therapeutics Receives Prestigious 2011 Apple Award for Top Publication in Breakthrough Spinal Cord Injury Research
Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2005
Size (employees)
30 (est)
InVivo Therapeutics was founded in 2005 and is headquartered in Cambridge, US

Key People at InVivo Therapeutics

Mark D. Perrin

Mark D. Perrin

CEO/Director
Kenneth DiPietro

Kenneth DiPietro

Director
Christopher McNulty

Christopher McNulty

Vice President, Business Development

InVivo Therapeutics Office Locations

InVivo Therapeutics has an office in Cambridge
Cambridge, US (HQ)
1 Kendall Square

InVivo Therapeutics Data and Metrics

InVivo Therapeutics Financial Metrics

Numbers are in $, USD

Net income (FY, 2016)

(23.4 m)

EBIT (FY, 2016)

(24.1 m)

Market capitalization (24-May-2017)

67.5 m

Closing share price (24-May-2017)

2

Cash (31-Dec-2016)

21.5 m
InVivo Therapeutics's current market capitalization is $67.5 m.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

R&D expense

10.5 m10.3 m10.1 m12.6 m

General and administrative expense

8.5 m7.6 m12.3 m11.5 m

Operating expense total

19 m17.8 m22.4 m24.1 m

EBIT

(19 m)(17.8 m)(22.4 m)(24.1 m)

Interest expense

(129.9 k)(136 k)(172 k)(155 k)

Interest income

15.3 k5 k60 k187 k

Net Income

(38.8 m)(18.3 m)(33.3 m)(23.4 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

14 m13.5 m20.2 m21.5 m

Inventories

20.1 k1.1 m184 k451 k

Current Assets

14.6 m15 m20.7 m33.9 m

PP&E

2.3 m1.6 m938 k510 k

Total Assets

17.1 m16.7 m21.8 m34.8 m

Accounts Payable

899.3 k569 k521 k1 m

Current Liabilities

2.3 m9.2 m3.3 m4.8 m

Additional Paid-in Capital

94.8 m106.2 m150.5 m186 m

Retained Earnings

(100.3 m)(133.6 m)(157 m)

Total Equity

12.9 m5.9 m16.9 m28.9 m

Financial Leverage

1.3 x2.8 x1.3 x1.2 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(38.8 m)(18.3 m)(33.3 m)(23.4 m)

Depreciation and Amortization

740.7 k752 k689 k553 k

Accounts Payable

(253.3 k)(330 k)(48 k)489 k

Cash From Operating Activities

(14.9 m)(15.3 m)(16.3 m)(16.7 m)

Purchases of PP&E

(748.5 k)(47 k)(5 k)(107 k)

Cash From Investing Activities

(748.5 k)(2 k)(5 k)(6.5 m)

Cash From Financing Activities

16.8 m14.8 m23.1 m29.8 m

Interest Paid

125.3 k132 k121 k103 k
Y, 2016

Financial Leverage

1.2 x

InVivo Therapeutics Operating Metrics

FY, 2016

Patents (foreign)

8

Patents (US)

8

Patents Pending

12

Facilities

1

InVivo Therapeutics Market Value History

InVivo Therapeutics Online and Social Media Presence

InVivo Therapeutics Company Life and Culture

You may also be interested in